Get the Stockscreener App
50.04
1.30%
-0.66
After Hours:
50.04
Mirum Pharmaceuticals Inc stock is traded at $50.04, with a volume of 390.69K.
It is down -1.30% in the last 24 hours and up +15.51% over the past month.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
See More
Previous Close:
$50.70
Open:
$51.02
24h Volume:
390.69K
Relative Volume:
0.90
Market Cap:
$2.40B
Revenue:
$307.03M
Net Income/Loss:
$-99.81M
P/E Ratio:
-24.18
EPS:
-2.0695
Net Cash Flow:
$-27.20M
1W Performance:
-2.00%
1M Performance:
+15.51%
6M Performance:
+20.61%
1Y Performance:
+75.76%
1-Day Range:
$49.97
$51.38
1-Week Range:
$48.53
$51.83
52-Week Range:
$23.14
$53.49
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
Name
Mirum Pharmaceuticals Inc
Sector
Industry
Phone
650-667-4085
Address
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
Compare MIRM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
50.04 | 2.40B | 307.03M | -99.81M | -27.20M | -2.0695 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.00 | 117.92B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
673.60 | 73.64B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
639.41 | 38.85B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
256.45 | 33.20B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.83 | 28.73B | 3.30B | -501.07M | 1.03B | -2.1146 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-17-24 | Initiated | Stifel | Buy |
| Dec-18-23 | Reiterated | H.C. Wainwright | Buy |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Nov-13-23 | Initiated | Morgan Stanley | Overweight |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-17-23 | Resumed | Evercore ISI | Outperform |
| Sep-20-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Sep-20-21 | Initiated | JP Morgan | Overweight |
| Aug-07-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-03-20 | Initiated | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jun-25-20 | Initiated | Robert W. Baird | Outperform |
| Aug-12-19 | Initiated | Citigroup | Buy |
| Aug-12-19 | Initiated | Evercore ISI | Outperform |
| Aug-12-19 | Initiated | Guggenheim | Buy |
| Aug-12-19 | Initiated | ROTH Capital | Buy |
| Aug-12-19 | Initiated | Raymond James | Outperform |
View All
Mirum Pharmaceuticals Inc Stock (MIRM) Latest News
Alagille Syndrome Market Expected to rise, 2034 | Mirum Pharmaceuticals, Albireo, expected to drive market - Barchart
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Mirum Pharma (MIRM) Unveils Strategic Talent Package: 74K Shares in Equity Grants - StockTitan
SG Americas Securities LLC Sells 13,575 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - MarketBeat
Insider Selling: Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Sells 1,064 Shares of Stock - MarketBeat
Mirum Pharmaceuticals (NASDAQ:MIRM) Hits New 52-Week HighHere's What Happened - MarketBeat
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Sells $126,673.94 in Stock - MarketBeat
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CEO Christopher Peetz Sells 9,102 Shares - MarketBeat
(MIRM) Technical Pivots with Risk Controls - Stock Traders Daily
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Golden State Equity Partners Has $801,000 Stock Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - MarketBeat
Genomenon and Mirum Pharmaceuticals Join Forces to Enhance CTX Disease Awareness and Diagnosis - PR Web
Mirum Pharmaceuticals president sells $126,680 in stock - MSN
Mirum Pharmaceuticals (NASDAQ:MIRM) shareholder returns have been solid, earning 192% in 5 years - Simply Wall St
Major Insider Stock Sales at Mirum Pharmaceuticals! - TipRanks
Mirum Pharmaceuticals president sells $126,680 in stock By Investing.com - Investing.com Canada
Mirum Pharmaceuticals (NASDAQ:MIRM) Reaches New 1-Year HighShould You Buy? - MarketBeat
Mirum Pharmaceuticals stock soars to all-time high of $49.59 - MSN
First Week of MIRM March 21st Options Trading - Nasdaq
Mirum Pharmaceuticals stock soars to all-time high of $49.59 By Investing.com - Investing.com UK
Recent Price Trend in Mirum Pharmaceuticals (MIRM) is Your Friend, Here's Why - Yahoo Finance
Mirum Pharmaceuticals stock soars to all-time high of $48.94 - MSN
Mirum Pharmaceuticals SVP sells shares worth $43,227 By Investing.com - Investing.com Australia
Insider Selling: Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Sells 902 Shares of Stock - MarketBeat
Christopher Peetz Sells 6,837 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stock - MarketBeat
Mirum Pharmaceuticals CEO sells shares worth $327,658 By Investing.com - Investing.com Australia
Mirum Pharmaceuticals SVP sells shares worth $43,227 - Investing.com India
Mirum Pharmaceuticals CEO sells shares worth $327,658 - Investing.com India
Mirum Pharmaceuticals president sells $152,256 in stock By Investing.com - Investing.com Canada
(MIRM) Long Term Investment Analysis - Stock Traders Daily
Mirum Pharmaceuticals (MIRM) Upgraded to Buy: What Does It Mean for the Stock? - MSN
FY2024 EPS Estimates for MIRM Increased by Leerink Partnrs - MarketBeat
Leerink Partnrs Issues Optimistic Estimate for MIRM Earnings - Defense World
Mirum Pharmaceuticals (NASDAQ:MIRM) Reaches New 12-Month HighShould You Buy? - MarketBeat
As Biotech Trade Gets Wonky, I'm Eyeing Two Clinical-Stage Companies - RealMoney
Cantor Fitzgerald Comments on MIRM FY2025 Earnings - Defense World
Mirum Pharmaceuticals Inc Stock (MIRM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.81%
2.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):